Program: Monday (05.11.2007)

08:30 – 10:00

Room: Großer Saal

Scientific Session Survivorship

  • Sandra Horning
  • Flora van Leeuwen
  • Screening in High Risk Groups

    • John Radford
  • Pulmonary and Cardiac Toxicity in HL Survivors

    • Flora van Leeuwen
  • How to Preserve Fertility in HL Patients

    • Michael von Wolf
  • Efficacy and Toxicity of Treatment of HL /Mature Data from a Single Centre

    • Richard Ward
  • Causes of Death and Excess Mortality after HL: the EORTC-GELA Experience

    • Olav Favier
  • Survival Patterns among HL Patients with a Family History of Lymphoma

    • Ola Landgren

10:30 – 12:00

Room: Großer Saal

Scientific Session Early Stage HL

  • Patrice Carde
  • David Straus
  • Defining the Role of Radiation Therapy (RT)

    • Richard Hoppe
  • Chemotherapy Only

    • Joseph Connors
  • Combined Modality Approaches

    • Andreas Engert
  • Results of the EORTC-GELA H9 Randomized Trials: the H9-F Trial (Comparing 3 Radiation Dose Levels) and H9-U Trial (Comparing 3 Chemotherapy Schemes) in Patients with Favorable or Unfavorable Early Stage HL

    • Jose Thomas
  • Stage I/II HL with Bulky Mediastinal Disease or other Risk Factors; The Stanford V Experience

    • Ranjana Advani
  • Chemotherapy is Essential for Optimal Treatment of Limited Stage Nodular Lymphocyte Predominant HL

    • Kerry J. Savage

12:15 – 13:45

Room: Großer Saal

Satellite Symposium (by Sigma-Tau) Procarbazine: An Established Drug with a New Life

  • Uwe Schlegel
  • Wolfgang Wick
  • Hodgkin Lymphoma: Better Cure with or without Procarbazine?

    • Volker Diehl
  • Therapy of primary CNS-Lymphomas: What’s new?

    • Uwe Schlegel
  • Molecular Predictors and Prognostic Markers in Brain Tumours.

    • Andreas von Deimling
  • What can we learn from Randomized Trials with Patients with Anaplastic Gliomas?

    • Wolfgang Wick
  • Investing in the Future of Cancer Patients

    • Alessandro Noseda
  • Summary and Closing Remarks

    • Volker Diehl

14:00 – 15:30

Room: Großer Saal

Scientific Session Relapsed and Refractory Disease

  • Ralph Naumann
  • Norbert Schmitz
  • GHSG Trials in Relapsed HL

    • Peter Borchmann
  • The Role of Gemcitabine in the Treatment of Primary and Relapsed Disease

    • George Canellos
  • New Agents

    • Anas Younes
  • Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone (IGEV) and Fixed Dose of Lenograstim: an Effective Mobilization Regimen in Pretreated HL Patients

    • Massimo Magagnoli
  • A Phase II Study of MGCD0103, a Novel Oral Isotype-Selective Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory HL

    • Anas Younes
  • Promising Results for Patients with Relapsed or Refractory HL Treated with the Oral mTOR Inhibitor Everolimus (RAD001)

    • Patrick Johnston

16:00 – 17:30

Room: Großer Saal

Scientific Session Translational Research

  • Martin-Leo Hansmann
  • Ruth Jarrett
  • Biological Risk Factors for Stratification of HL Patients

    • Ruth Jarrett
  • The Role of the Microenvironment in HL

    • Randy Gascoyne
  • Analysing Differential Gene Expression and Genetic Lesions in HRS and L&H Cells to Identify New Therapeutic Targets

    • Ralf Küppers
  • Latent EBV Infection of HRS Cells Predicts Adverse Outcome in Older Adult Classical HL Patients

    • Arjan Diepstra
  • A Taqman-Low Density Array to Predict Outcome in HL Using Paraffin Embedded Samples

    • Beatriz Sanchez-Espiridion
  • Associations between Plasma Levels and Promoter Genotypes of IL-10 and IL-6 with Patient Characteristics and Outcome in HL

    • Stefan Hohaus

17:30 – 18:45

Room: Großer Saal

Main Program Key Note Lecture

  • The Role of Innate Immunity in Cancer Progression

    • Lisa Coussens

19:00 – 20:00

Room: Großer Saal

Satellite Symposium (by Chugai Pharma) Therapy of HL: Efficacy and Long Term Safety

  • Sandra Horning
  • Glycosylated G-CSF Mobilises More Clonogenic Progentiors than Non-Glycosylated G-CSF

    • Mike Watts
  • Treatment Associated Long Term Toxicity in HL Patients

    • Daniel Re


You a viewing the program of a past symposium. Click here to get back to the current conference.